|
|
| Product Name: | ML355 | | Synonyms: | N-2-Benzothiazolyl-4-[[(2-hydroxy-3-methoxyphenyl)methyl]amino]benzenesulfonamide;ML 355;ML-355;ML355;N-(benzo[d]thiazol-2-yl)-4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide;ML355;Benzenesulfonamide, N-2-benzothiazolyl-4-[[(2-hydroxy-3-methoxyphenyl)methyl]amino]-;ML355,LOX,ML-355,Lipoxygenase,Inhibitor,inhibit,ML 355;12-LOX enzyme inhibitor;VLX 1005 | | CAS: | 1532593-30-8 | | MF: | C21H19N3O4S2 | | MW: | 441.52 | | EINECS: | | | Product Categories: | API | | Mol File: | 1532593-30-8.mol |  |
| | ML355 Chemical Properties |
| Melting point | >182°C (dec.) | | Boiling point | 654.5±65.0 °C(Predicted) | | density | 1.481±0.06 g/cm3(Predicted) | | storage temp. | -20°C Freezer, Under inert atmosphere | | solubility | DMSO (Slightly), Pyridine (Very Slightly) | | form | Solid | | pka | 7.58±0.30(Predicted) | | color | Pale Beige to Beige |
| | ML355 Usage And Synthesis |
| Uses | ML355 is used in the synthesis, structural activity relationship of benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase. | | in vivo | ML355 (1.88-30 mg/kg; i.g.; 2 times per day for two days) strongly inhibits the thrombus formation in mice at higher dose compared to WT controls[3]. | Animal Model: | C57BL/6 mice[3] | | Dosage: | 1.88, 3.75, 7.5, 15, 30 mg/kg | | Administration: | Oral gavage; 2 times per day for two days | | Result: | The thrombus formation in mice was strongly inhibited by higher doses of ML355. |
| | IC 50 | 12-LOX: 0.34 μM (IC50) |
| | ML355 Preparation Products And Raw materials |
|